EP0475255A3
(en)
|
1990-09-12 |
1993-04-14 |
F. Hoffmann-La Roche Ag |
Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
|
JP4080541B2
(ja)
|
1996-10-18 |
2008-04-23 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
|
ES2241157T3
(es)
|
1997-08-11 |
2005-10-16 |
Boehringer Ingelheim (Canada) Ltd. |
Peptidos inhibidores de la hepatitis c.
|
EP1012180B1
(en)
|
1997-08-11 |
2004-12-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor peptide analogues
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
AR022061A1
(es)
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
US6608027B1
(en)
*
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
UA74546C2
(en)
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
US7012066B2
(en)
|
2000-07-21 |
2006-03-14 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
HUP0500456A3
(en)
|
2000-11-20 |
2012-05-02 |
Bristol Myers Squibb Co |
Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use
|
US6867185B2
(en)
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
CA2369711A1
(en)
|
2002-01-30 |
2003-07-30 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis c virus
|
CA2369970A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
CA2370396A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US6828301B2
(en)
|
2002-02-07 |
2004-12-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for hepatitis C viral protease inhibitors
|
US20060199773A1
(en)
|
2002-05-20 |
2006-09-07 |
Sausker Justin B |
Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
ES2315568T3
(es)
|
2002-05-20 |
2009-04-01 |
Bristol-Myers Squibb Company |
Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
|
ATE481106T1
(de)
|
2002-05-20 |
2010-10-15 |
Bristol Myers Squibb Co |
Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
|
EP1506172B1
(en)
|
2002-05-20 |
2011-03-30 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US20040033959A1
(en)
|
2002-07-19 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pharmaceutical compositions for hepatitis C viral protease inhibitors
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
KR100940619B1
(ko)
*
|
2003-02-07 |
2010-02-05 |
이난타 파마슈티칼스, 인코포레이티드 |
마크로사이클릭 씨형 간염 세린 단백효소 억제제
|
EP1601685A1
(en)
|
2003-03-05 |
2005-12-07 |
Boehringer Ingelheim International GmbH |
Hepatitis c inhibiting compounds
|
DE602004029866D1
(de)
|
2003-03-05 |
2010-12-16 |
Boehringer Ingelheim Pharma |
Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
|
KR20050108420A
(ko)
|
2003-04-02 |
2005-11-16 |
베링거 인겔하임 인터내셔날 게엠베하 |
C형 간염 바이러스 프로테아제 억제제를 위한 약제학적조성물
|
ATE422895T1
(de)
*
|
2003-04-16 |
2009-03-15 |
Bristol Myers Squibb Co |
Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
|
PT1615613E
(pt)
|
2003-04-18 |
2010-02-09 |
Enanta Pharm Inc |
Inibidores da serina protease da hepatite c macrocíclicos de quinoxalinilo
|
PT1654261E
(pt)
|
2003-05-21 |
2008-01-18 |
Boehringer Ingelheim Int |
Compostos inibidores da hepatite c
|
WO2004113365A2
(en)
|
2003-06-05 |
2004-12-29 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c serine protease tri-peptide inhibitors
|
US7125845B2
(en)
|
2003-07-03 |
2006-10-24 |
Enanta Pharmaceuticals, Inc. |
Aza-peptide macrocyclic hepatitis C serine protease inhibitors
|
DE602004031645D1
(de)
|
2003-09-22 |
2011-04-14 |
Boehringer Ingelheim Pharma |
Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
|
CA2541634A1
(en)
|
2003-10-10 |
2005-04-28 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
DK1680137T3
(da)
|
2003-10-14 |
2013-02-18 |
Hoffmann La Roche |
Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1689770A1
(en)
|
2003-11-20 |
2006-08-16 |
Schering Corporation |
Depeptidized inhibitors of hepatitis c virus ns3 protease
|
CA2549851C
(en)
|
2004-01-21 |
2012-09-11 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis c virus
|
AR048401A1
(es)
|
2004-01-30 |
2006-04-26 |
Medivir Ab |
Inhibidores de la serina-proteasa ns3 del vhc
|
RU2006136084A
(ru)
|
2004-03-15 |
2008-04-27 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Способ получения микроциклических соединений
|
BRPI0509467A
(pt)
|
2004-03-30 |
2007-09-11 |
Intermune Inc |
compostos macrocìclicos como inibidores de replicação viral
|
WO2006016930A2
(en)
|
2004-05-14 |
2006-02-16 |
Intermune, Inc. |
Methods for treating hcv infection
|
JP5156374B2
(ja)
|
2004-05-25 |
2013-03-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
非環式hcvプロテアーゼインヒビターの調製方法
|
CA2556669C
(en)
|
2004-06-28 |
2012-05-01 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
AR050174A1
(es)
|
2004-07-16 |
2006-10-04 |
Gilead Sciences Inc |
Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
EP1771454B1
(en)
|
2004-07-20 |
2011-06-15 |
Boehringer Ingelheim International GmbH |
Hepatitis c inhibitor peptide analogs
|
US7550559B2
(en)
|
2004-08-27 |
2009-06-23 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
|
JP2008513454A
(ja)
|
2004-09-17 |
2008-05-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
大環状hcvプロテアーゼインヒビターの調製方法
|
WO2007001406A2
(en)
|
2004-10-05 |
2007-01-04 |
Chiron Corporation |
Aryl-containing macrocyclic compounds
|
CA2583152A1
(en)
|
2004-10-21 |
2006-04-27 |
Pfizer Inc. |
Inhibitors of hepatitis c virus protease, and compositions and treatments using the same
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN101160317B
(zh)
|
2005-03-08 |
2013-03-27 |
贝林格尔·英格海姆国际有限公司 |
制备大环化合物的方法
|
US7879797B2
(en)
|
2005-05-02 |
2011-02-01 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2006130554A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis c virus
|
NZ563365A
(en)
|
2005-06-02 |
2011-02-25 |
Schering Corp |
Combination of HCV protease inhibitors with a surfactant
|
US20060276406A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis C virus
|
US20060276405A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods for treating hepatitis C
|
US20070004635A1
(en)
|
2005-06-02 |
2007-01-04 |
Schering Corporation |
Method of treating interferon non-responders using HCV protease inhibitor
|
US20060281689A1
(en)
|
2005-06-02 |
2006-12-14 |
Schering Corporation |
Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
|
US20070021351A1
(en)
|
2005-06-02 |
2007-01-25 |
Schering Corporation |
Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
|
US8119602B2
(en)
|
2005-06-02 |
2012-02-21 |
Schering Corporation |
Administration of HCV protease inhibitors in combination with food to improve bioavailability
|
US20060287248A1
(en)
|
2005-06-02 |
2006-12-21 |
Schering Corporation |
Asymmetric dosing methods
|
US20060276404A1
(en)
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
WO2006130607A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation useful for treating disorders associated with hepatitis c virus
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
TW200738742A
(en)
|
2005-07-14 |
2007-10-16 |
Gilead Sciences Inc |
Antiviral compounds
|
TWI389908B
(zh)
|
2005-07-14 |
2013-03-21 |
Gilead Sciences Inc |
抗病毒化合物類
|
TWI387603B
(zh)
|
2005-07-20 |
2013-03-01 |
Merck Sharp & Dohme |
Hcv ns3蛋白酶抑制劑
|
EP1910378B1
(en)
|
2005-07-20 |
2012-06-20 |
Boehringer Ingelheim International GmbH |
Hepatitis c inhibitor peptide analogs
|
JP5249028B2
(ja)
|
2005-07-25 |
2013-07-31 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規大環状阻害剤
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
MX2008001402A
(es)
|
2005-07-29 |
2008-04-04 |
Tibotec Pharm Ltd |
Inhibidores macrociclicos del virus de la hepatitis c.
|
JO2768B1
(en)
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
PE20070210A1
(es)
|
2005-07-29 |
2007-04-16 |
Tibotec Pharm Ltd |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
CN101273030B
(zh)
|
2005-07-29 |
2012-07-18 |
泰博特克药品有限公司 |
丙型肝炎病毒的大环抑制剂
|
PE20070343A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Inhibidores macrociclicos del virus de la hepatitis c
|
TW200745061A
(en)
|
2005-07-29 |
2007-12-16 |
Tibotec Pharm Ltd |
Macrocylic inhibitors of hepatitis C virus
|
CN101273042B
(zh)
|
2005-07-29 |
2013-11-06 |
泰博特克药品有限公司 |
丙型肝炎病毒的大环抑制剂
|
ATE496042T1
(de)
|
2005-07-29 |
2011-02-15 |
Tibotec Pharm Ltd |
Makrocyclische inhibitoren des hepatitis-c-virus
|
TWI375670B
(en)
|
2005-07-29 |
2012-11-01 |
Tibotec Pharm Ltd |
Macrocylic inhibitors of hepatitis c virus
|
RU2419619C2
(ru)
|
2005-07-29 |
2011-05-27 |
Медивир Аб |
Макроциклические ингибиторы вируса гепатита с
|
JP2009503084A
(ja)
|
2005-08-01 |
2009-01-29 |
フェノミックス コーポレーション |
C型肝炎セリンプロテアーゼ阻害剤およびその使用
|
KR20080036598A
(ko)
|
2005-08-01 |
2008-04-28 |
머크 앤드 캄파니 인코포레이티드 |
Hcv ns3 프로테아제 억제제로서의 마크로사이클릭펩티드
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
CA2621360C
(en)
|
2005-09-09 |
2013-12-24 |
Boehringer Ingelheim International Gmbh |
Ring-closing metathesis process for the preparation of macrocyclic peptides
|
DE602006019323D1
(de)
|
2005-10-11 |
2011-02-10 |
Intermune Inc |
Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2007082131A1
(en)
|
2006-01-09 |
2007-07-19 |
Bristol-Myers Squibb Company |
Process for the preparation of hydroxy substituted heterocycles
|
WO2007106317A2
(en)
|
2006-03-03 |
2007-09-20 |
Schering Corporation |
Pharmaceutical combinations of hcv-protease and -ires inhibitors
|
WO2007120595A2
(en)
|
2006-04-11 |
2007-10-25 |
Novartis Ag |
Amines for the treatment of hcv
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
US20070281884A1
(en)
|
2006-06-06 |
2007-12-06 |
Ying Sun |
Macrocyclic oximyl hepatitis C protease inhibitors
|
US8268776B2
(en)
|
2006-06-06 |
2012-09-18 |
Enanta Pharmaceuticals, Inc. |
Macrocylic oximyl hepatitis C protease inhibitors
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
UY30437A1
(es)
|
2006-06-26 |
2008-01-31 |
Enanta Pharm Inc |
Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
|
KR20090024834A
(ko)
|
2006-07-05 |
2009-03-09 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 억제제
|
CA2656356C
(en)
|
2006-07-07 |
2013-04-09 |
Gilead Sciences, Inc. |
Antiviral phosphinate compounds
|
WO2008008776A2
(en)
|
2006-07-11 |
2008-01-17 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EA017448B1
(ru)
|
2006-07-13 |
2012-12-28 |
Ачиллион Фармасьютикалз, Инк. |
4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
|
WO2008019303A2
(en)
|
2006-08-04 |
2008-02-14 |
Enanta Pharmaceuticals, Inc. |
Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
|
WO2008019289A2
(en)
|
2006-08-04 |
2008-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
|
US20090035267A1
(en)
|
2007-07-31 |
2009-02-05 |
Moore Joel D |
Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
|
US7635683B2
(en)
|
2006-08-04 |
2009-12-22 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl tripeptide hepatitis C virus inhibitors
|
US20080038225A1
(en)
|
2006-08-11 |
2008-02-14 |
Ying Sun |
Triazolyl acyclic hepatitis c serine protease inhibitors
|
WO2008021960A2
(en)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Triazolyl macrocyclic hepatitis c serine protease inhibitors
|
US7582605B2
(en)
|
2006-08-11 |
2009-09-01 |
Enanta Pharmaceuticals, Inc. |
Phosphorus-containing hepatitis C serine protease inhibitors
|
US7605126B2
(en)
|
2006-08-11 |
2009-10-20 |
Enanta Pharmaceuticals, Inc. |
Acylaminoheteroaryl hepatitis C virus protease inhibitors
|
US20090035268A1
(en)
|
2007-08-01 |
2009-02-05 |
Ying Sun |
Tetrazolyl acyclic hepatitis c serine protease inhibitors
|
WO2008022006A2
(en)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis c virus protease inhibitors
|
US8138164B2
(en)
|
2006-10-24 |
2012-03-20 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
WO2008051514A2
(en)
|
2006-10-24 |
2008-05-02 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
AU2007309546A1
(en)
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
CA2667031C
(en)
|
2006-10-27 |
2013-01-22 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
CN101568346B
(zh)
|
2006-10-27 |
2015-11-25 |
默沙东公司 |
Hcv ns3蛋白酶抑制剂
|
US20080107625A1
(en)
|
2006-11-01 |
2008-05-08 |
Bristol-Myers Squibb Company |
Inhibitors of Hepatitis C Virus
|
US20080107623A1
(en)
|
2006-11-01 |
2008-05-08 |
Bristol-Myers Squibb Company |
Inhibitors of Hepatitis C Virus
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US20080108632A1
(en)
|
2006-11-02 |
2008-05-08 |
Taigen Biotechnology Co., Ltd. |
Hcv protease inhibitors
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2008070358A2
(en)
|
2006-11-16 |
2008-06-12 |
Phenomix Corporation |
N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
|
WO2008059046A1
(en)
|
2006-11-17 |
2008-05-22 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis c virus
|
KR20090101372A
(ko)
|
2007-01-08 |
2009-09-25 |
페노믹스 코포레이션 |
매크로시클릭 c형 간염 프로테아제 억제제
|
PT2121674E
(pt)
|
2007-02-01 |
2010-09-03 |
Tibotec Pharm Ltd |
Processos e intermediários para a preparação de um inibidor macrocíclico da protease do hcv
|
WO2008095058A1
(en)
|
2007-02-01 |
2008-08-07 |
Taigen Biotechnology Co. Ltd. |
Hcv protease inhibitors
|
CN105037347B
(zh)
|
2007-02-01 |
2018-06-01 |
泰博特克药品有限公司 |
Hcv巨环抑制剂的多晶形
|
WO2008096001A1
(en)
|
2007-02-08 |
2008-08-14 |
Tibotec Pharmaceuticals Ltd. |
Hcv inhibiting macrocyclic phenylcarbamates
|
WO2008096002A1
(en)
|
2007-02-08 |
2008-08-14 |
Tibotec Pharmaceuticals Ltd. |
Hcv inhibiting macrocyclic phosphonates and amidophosphates
|
EP2118091B1
(en)
|
2007-02-08 |
2015-04-15 |
Janssen Sciences Ireland UC |
Pyrimidine substituted macrocyclic hcv inhibitors
|
WO2008098368A1
(en)
|
2007-02-16 |
2008-08-21 |
Boehringer Ingelheim International Gmbh |
Inhibitors of hepatitis c ns3 protease
|
AU2008217187A1
(en)
|
2007-02-20 |
2008-08-28 |
Novartis Ag |
Macrocyclic compounds as HCV NS3 protease inhibitors
|
EP2495249A1
(en)
|
2007-02-26 |
2012-09-05 |
Achillion Pharmaceuticals, Inc. |
Tertiary amine substituted peptides useful as inhibitors of HCV replication
|
AU2008240834B2
(en)
|
2007-04-24 |
2012-08-23 |
F. Hoffmann-La Roche Ag |
Process for HCV protease inhibitor intermediate
|
WO2008134397A1
(en)
|
2007-04-26 |
2008-11-06 |
Enanta Pharmaceuticals, Inc. |
Aza-tripeptide hepatitis c serine protease inhibitors
|
US20080292587A1
(en)
|
2007-04-26 |
2008-11-27 |
Ying Sun |
Oximyl dipeptide hepatitis c protease inhibitors
|
US20080279821A1
(en)
|
2007-04-26 |
2008-11-13 |
Deqiang Niu |
Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
|
WO2008134395A1
(en)
|
2007-04-26 |
2008-11-06 |
Enanta Pharmaceuticals, Inc. |
Aza-peptide macrocyclic hepatitis c serine protease inhibitors
|
EP2177523A1
(en)
|
2007-05-03 |
2010-04-21 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
JP2010526834A
(ja)
|
2007-05-10 |
2010-08-05 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規ペプチド阻害剤
|
AR067180A1
(es)
|
2007-06-29 |
2009-09-30 |
Gilead Sciences Inc |
Compuestos antivirales
|
EP2162431B1
(en)
|
2007-06-29 |
2017-06-07 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US8513186B2
(en)
|
2007-06-29 |
2013-08-20 |
Gilead Sciences, Inc. |
Antiviral compounds
|
WO2009010804A1
(en)
|
2007-07-19 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic compounds as antiviral agents
|
WO2009014730A1
(en)
|
2007-07-26 |
2009-01-29 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
CN104016970A
(zh)
|
2007-10-10 |
2014-09-03 |
诺华股份有限公司 |
螺环吡咯烷类与其对抗hcv和hiv感染的应用
|
WO2009053828A2
(en)
|
2007-10-22 |
2009-04-30 |
Enanta Pharmaceuticals, Inc. |
P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
|
WO2009055335A2
(en)
|
2007-10-25 |
2009-04-30 |
Taigen Biotechnology Co., Ltd. |
Hcv protease inhibitors
|
CL2008003384A1
(es)
|
2007-11-14 |
2009-12-11 |
Enanta Pharm Inc |
Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
|
WO2009064955A1
(en)
|
2007-11-14 |
2009-05-22 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic tetrazolyl hepatitis c serine protease inhibitors
|
WO2009070692A1
(en)
|
2007-11-29 |
2009-06-04 |
Enanta Pharmaceuticals, Inc. |
C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
|
WO2009070689A1
(en)
|
2007-11-29 |
2009-06-04 |
Enanta Pharmaceuticals, Inc. |
Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
|
CN101932242A
(zh)
|
2007-12-05 |
2010-12-29 |
益安药业 |
喹喔啉基衍生物
|
WO2009076173A2
(en)
|
2007-12-05 |
2009-06-18 |
Enanta Pharmaceuticals, Inc. |
Fluorinated tripeptide hcv serine protease inhibitors
|
US8361958B2
(en)
|
2007-12-05 |
2013-01-29 |
Enanta Pharmaceuticals, Inc. |
Oximyl HCV serine protease inhibitors
|
US8268777B2
(en)
|
2007-12-05 |
2012-09-18 |
Enanta Pharmaceuticals, Inc. |
Oximyl macrocyclic derivatives
|
CA2708047A1
(en)
|
2007-12-06 |
2009-06-11 |
Enanta Pharmaceuticals, Inc. |
Process for making macrocyclic oximyl hepatitis c protease inhibitors
|
WO2009079353A1
(en)
|
2007-12-14 |
2009-06-25 |
Enanta Pharmaceuticals, Inc. |
Triazole-containing macrocyclic hcv serine protease inhibitors
|
MX2010006518A
(es)
|
2007-12-14 |
2010-08-10 |
Enanta Pharm Inc |
Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
|
WO2009082701A1
(en)
|
2007-12-21 |
2009-07-02 |
Avila Therapeutics, Inc. |
Hcv protease inhibitors and uses thereof
|
US8309685B2
(en)
|
2007-12-21 |
2012-11-13 |
Celgene Avilomics Research, Inc. |
HCV protease inhibitors and uses thereof
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
MX2010006659A
(es)
|
2007-12-21 |
2010-07-05 |
Hoffmann La Roche |
Proceso para la preparacion de un macrociclo.
|
US8293705B2
(en)
|
2007-12-21 |
2012-10-23 |
Avila Therapeutics, Inc. |
HCV protease inhibitors and uses thereof
|
CA2709535A1
(en)
|
2007-12-21 |
2009-07-02 |
Avila Therapeutics, Inc. |
Hcv protease inhibitors and uses thereof
|
CN102036966A
(zh)
|
2008-01-24 |
2011-04-27 |
益安药业 |
作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽
|
US8101567B2
(en)
|
2008-01-24 |
2012-01-24 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl-containing tripeptide HCV serine protease inhibitors
|
WO2009108507A1
(en)
|
2008-02-25 |
2009-09-03 |
Merck & Co., Inc. |
Therapeutic compounds
|
CN102015652A
(zh)
|
2008-03-20 |
2011-04-13 |
益安药业 |
作为丙型肝炎病毒抑制剂的氟化大环化合物
|
SG175692A1
(en)
|
2008-04-15 |
2011-11-28 |
Intermune Inc |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2720850A1
(en)
|
2008-04-28 |
2009-11-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
WO2009134987A1
(en)
|
2008-04-30 |
2009-11-05 |
Enanta Pharmaceuticals, Inc. |
Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
|
US20090285773A1
(en)
|
2008-05-15 |
2009-11-19 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US20090285774A1
(en)
|
2008-05-15 |
2009-11-19 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
CN101580535B
(zh)
|
2008-05-16 |
2012-10-03 |
太景生物科技股份有限公司 |
丙型肝炎病毒蛋白酶抑制剂
|
JP5529120B2
(ja)
|
2008-05-29 |
2014-06-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
PL2310095T3
(pl)
|
2008-07-22 |
2013-03-29 |
Msd Italia Srl |
Makrocykliczne związki chinoksaliny jako inhibitory proteazy NS3 HCV
|
CA2732091A1
(en)
|
2008-08-07 |
2010-02-11 |
F. Hoffmann-La Roche Ag |
Process for the preparation of a macrocycle
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
WO2010033466A1
(en)
|
2008-09-16 |
2010-03-25 |
Phenomix Corporation |
Macrocyclic inhibitors of hepatitis c protease
|
TW201023858A
(en)
|
2008-09-18 |
2010-07-01 |
Ortho Mcneil Janssen Pharm |
Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
|
WO2010031832A2
(en)
|
2008-09-18 |
2010-03-25 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc |
Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
|
CA2737958A1
(en)
|
2008-09-23 |
2010-04-01 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US20100080770A1
(en)
|
2008-09-29 |
2010-04-01 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2743912A1
(en)
|
2008-11-20 |
2010-05-27 |
Achillion Pharmaceuticals, Inc. |
Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
|
US20100272674A1
(en)
|
2008-12-04 |
2010-10-28 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
CA2746265A1
(en)
|
2008-12-10 |
2010-06-17 |
Achillion Pharmaceuticals, Inc. |
4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
|
SI2364309T1
(sl)
|
2008-12-10 |
2015-03-31 |
Achillion Pharmaceuticals, Inc. |
Novi 4-amino-4-oksobutanoil peptidi kot inhibitorji virusne replikacije
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2379579A1
(en)
|
2008-12-19 |
2011-10-26 |
Gilead Sciences, Inc. |
Hcv ns3 protease inhibitors
|
JP2012513397A
(ja)
|
2008-12-22 |
2012-06-14 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルス化合物
|
WO2010088394A1
(en)
|
2009-01-30 |
2010-08-05 |
Glaxosmithkline Llc |
Compounds
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
EP2429568B1
(en)
|
2009-05-13 |
2016-08-17 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic compounds as hepatitis c virus inhibitors
|
CN101921308A
(zh)
|
2009-06-16 |
2010-12-22 |
上海唐润医药科技有限公司 |
具有抗hcv活性的化合物及其用途
|
US8232246B2
(en)
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
CA2767692C
(en)
|
2009-07-07 |
2017-03-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition for a hepatitis c viral protease inhibitor
|
WO2011014487A1
(en)
|
2009-07-30 |
2011-02-03 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
CA2770338A1
(en)
|
2009-08-27 |
2011-03-03 |
Merck Sharp & Dohme Corp. |
Processes for preparing protease inhibitors of hepatitis c virus
|
US8389560B2
(en)
|
2009-09-15 |
2013-03-05 |
Taigen Biotechnology Co., Ltd. |
HCV protease inhibitors
|
CA2775697A1
(en)
|
2009-09-28 |
2011-03-31 |
Intermune, Inc. |
Cyclic peptide inhibitors of hepatitis c virus replication
|
KR20120110090A
(ko)
|
2009-09-28 |
2012-10-09 |
에프. 호프만-라 로슈 리미티드 |
C형 간염 바이러스 복제의 신규한 마크로시클릭 저해제
|
TW201116540A
(en)
|
2009-10-01 |
2011-05-16 |
Intermune Inc |
Therapeutic antiviral peptides
|
US8415374B2
(en)
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
WO2011049908A2
(en)
|
2009-10-19 |
2011-04-28 |
Enanta Pharmaceuticals, Inc. |
Bismacrokyclic compounds as hepatitis c virus inhibitors
|
WO2011063501A1
(en)
|
2009-11-24 |
2011-06-03 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
EP2504344A4
(en)
|
2009-11-24 |
2013-06-05 |
Boehringer Ingelheim Int |
HEPATITIS C INHIBITOR COMPOUNDS
|
KR20120116404A
(ko)
|
2009-12-18 |
2012-10-22 |
베링거 인겔하임 인터내셔날 게엠베하 |
Hcv 병용 요법
|
AU2011209051B2
(en)
|
2010-01-27 |
2015-01-15 |
AB Pharma Ltd. |
Polyheterocyclic compounds highly potent as HCV inhibitors
|
WO2011150190A2
(en)
|
2010-05-26 |
2011-12-01 |
Anacor Pharmaceuticals, Inc. |
Hcv inhibitor compounds and methods of use thereof
|
JP2013528217A
(ja)
|
2010-06-07 |
2013-07-08 |
アッヴィ・インコーポレイテッド |
大環状c型肝炎セリンプロテアーゼ阻害薬
|
US20120196794A1
(en)
|
2010-08-06 |
2012-08-02 |
Bristol-Myers Squibb Company |
Combinations of Hepatitis C Virus Inhibitors
|
WO2012019299A1
(en)
|
2010-08-11 |
2012-02-16 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor compounds
|
US20120094897A1
(en)
|
2010-09-15 |
2012-04-19 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
US20130178413A1
(en)
|
2010-09-21 |
2013-07-11 |
John A. McCauley |
Hcv ns3 protease inhibitors
|
PE20140015A1
(es)
|
2010-09-21 |
2014-02-16 |
Enanta Pharm Inc |
Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
|
WO2012040242A1
(en)
|
2010-09-22 |
2012-03-29 |
Intermune, Inc. |
Substituted proline inhibitors of hepatitis c virus replication
|
WO2012047764A1
(en)
|
2010-10-04 |
2012-04-12 |
Intermune, Inc. |
Therapeutic antiviral peptides
|
US20120101032A1
(en)
|
2010-10-22 |
2012-04-26 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
EP2651884A2
(en)
|
2010-12-14 |
2013-10-23 |
Merck Sharp & Dohme Corp. |
Process and intermediates for preparing macrolactams
|
MX2013007677A
(es)
|
2010-12-30 |
2013-07-30 |
Abbvie Inc |
Inhibidores macrociclicos de serina proteasa de hepatitis.
|
AU2011352145A1
(en)
|
2010-12-30 |
2013-07-18 |
Abbvie Inc. |
Phenanthridine macrocyclic hepatitis C serine protease inhibitors
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2012166459A1
(en)
|
2011-05-27 |
2012-12-06 |
Bristol-Myers Squibb Company |
Tripeptides incorporating deuterium as inhibitors of hepatitis c virus
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR20140059236A
(ko)
|
2011-08-19 |
2014-05-15 |
머크 샤프 앤드 돔 코포레이션 |
Hcv 프로테아제 억제제의 결정 형태
|
EP2780026B1
(en)
|
2011-11-15 |
2019-10-23 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
US9040479B2
(en)
|
2012-01-12 |
2015-05-26 |
Cocrystal Pharma, Inc. |
HCV NS3 protease inhibitors
|
CN102617705B
(zh)
|
2012-02-16 |
2014-12-31 |
上海纬诺医药科技有限公司 |
抑制丙肝病毒复制的大环类化合物
|